MCH Negotiates Stake in Medical Distributor World Medica

Spanish private equity firm MCH is reportedly in advanced discussions to acquire a minority stake in World Medica, a significant player in the medical equipment distribution sector. This potential transaction, orchestrated through a competitive process managed by Abante, signals a strategic move by MCH to bolster its presence in the healthcare supply chain.

World Medica, established in 1999 and headquartered in Alcobendas, Madrid, has demonstrated robust financial performance, reporting approximately €34 million in revenue and an impressive €13 million in EBITDA for the fiscal year 2025. The company's core business involves the import, distribution, and commercialization of advanced medical devices, with a particular focus on technologies for minimally invasive procedures, hemodynamics, interventional radiology, and neuroradiology. Its operational footprint extends across Spain, Portugal, the United States, and the United Kingdom, serving a diverse clientele through partnerships with leading manufacturers such as Asahi Intecc, CardioValve, and Vygon.

The proposed investment by MCH is anticipated to fuel World Medica's ambitious growth agenda, particularly its international expansion and strategic acquisition initiatives. The company's founder, who will continue to steer the business post-investment, plans to leverage the capital infusion for a 'build-up' strategy. This involves acquiring smaller entities within the medical distribution space or those offering complementary services, aiming to achieve greater scale, operational synergies, enhanced profitability, and broader market penetration.

The medical device distribution market, a critical segment within the broader healthcare industry, is experiencing sustained growth driven by an aging global population, increasing demand for advanced medical technologies, and a growing emphasis on minimally invasive procedures. This sector, valued in the tens of billions globally, presents attractive opportunities for consolidation and value creation, making strategic investments like the one contemplated by MCH particularly relevant. Comparable successful partnerships, such as Palex's growth trajectory following investment from Corpfin and later Apax, and the performance of portfolio companies like Proclinic (backed by Miura Capital) and Nuzoa (supported by PAI Partners), underscore the potential for private equity involvement in this domain.

MCH's selection as the preferred investor follows a rigorous selection process, highlighting the firm's strategic alignment with World Medica's future vision. While neither MCH nor Abante have officially commented on the ongoing negotiations, market observers view this potential deal as a significant development for both parties. For MCH, it represents an opportunity to deepen its investment in a resilient and growing sector. For World Medica, it marks a pivotal step towards accelerating its strategic objectives and solidifying its market position.

The integration of new technologies and the expansion into new geographical territories are key components of World Medica's forward-looking strategy. The company's established network of suppliers and its proven track record in navigating complex regulatory environments provide a strong foundation for future growth. The anticipated partnership with MCH is expected to provide not only financial backing but also strategic guidance and operational expertise to support these endeavors.